The Role of Custom Antibodies in Neurological Disorders
Role of Custom Antibodies in Neurological Disorders
In choosing medical laboratory tips diseases such as Alzheimer’s disease, ALS or MS, autoantibodies can act as biomarkers, indicating the presence of underlying disease mechanisms. Additionally, antibodies can directly target pathological proteins in the brain and thereby improve treatment efficacy. Moreover, by analyzing the unique antibody profile of patients, it is possible to identify selective therapy strategies.
Advances in Stem Cell Treatments: Emerging Therapies and Clinical Potential
The discovery of neuronal autoantibodies in a broad range of patients with neurological disorders has opened up new avenues for research and clinical applications. Often, these autoantibodies are detected in combination with other pathogenic markers in a patient’s polyclonal repertoire. For example, a patient with GABAAR encephalitis harbors autoantibodies to CASPR2, LGI1 and NMDAR in their antibody repertoire. This hints at the existence of a neuronal autoimmunity “super-system”, which may modulate the risk for neurological disease.
Similarly, the detection of anti-amyloid and anti-tau antibodies in a broad spectrum of patients with Alzheimer’s disease has led to the development of therapeutic antibodies, such as aducanumab or lecanemab, which aim to clear toxic aggregates of these proteins and thus potentially slow disease progression. Furthermore, advances in antibody engineering allow for bispecific therapies to simultaneously target multiple pathological proteins and thus increase therapeutic effect.
By combining the powerful sensitivity of immunoprecipitation with the high-throughput capabilities of mass spectrometry and antibody screening, we can identify novel targets and rapidly develop mAbs to those targets. mAbs are monoclonal antibodies that bind to an antigen on the surface of a target cell. Their small size, composed of only one variable domain in each heavy and light chain, makes them easier to enter tissues and allow for more accurate targeting in medical applications.